We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

98 hedge funds and large institutions have $145M invested in PMV Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

833% more call options, than puts

Call options by funds: $541K | Put options by funds: $58K

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

6% less funds holding

Funds holding: 104 → 98 (-6)

14% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 29

20.31% less ownership

Funds ownership: 111.92% → 91.61% (-20%)

56% less capital invested

Capital invested by funds: $333M → $145M (-$188M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
98
Holders Change
-6
Holders Change %
-5.77%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
25
Increased
32
Reduced
30
Closed
29
Calls
$541K
Puts
$58K
Net Calls
+$483K
Net Calls Change
-$1.89M

Top Buyers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
+$6.47M
2
Bank of America
Bank of America
North Carolina
+$3.42M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.03M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.99M
5
WP
Woodline Partners
California
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$19.4M
2
ACA
Avoro Capital Advisors
New York
-$18.4M
3
RI
RTW Investments
New York
-$14.6M
4
OCA
Octagon Capital Advisors
New York
-$5.55M
5
TLP
Tri Locum Partners
New York
-$5.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Silverarc Capital Management
Massachusetts
$1.71M +$1.46M +550,000 New
Citigroup
27
Citigroup
New York
$1.61M +$410K +155,043 +42%
Barclays
28
Barclays
United Kingdom
$1.6M +$123K +46,352 +10%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$1.33M +$1.14M +429,642 New
Northern Trust
30
Northern Trust
Illinois
$1.01M -$33.1K -12,505 -4%
BBA
31
Baker Bros. Advisors
New York
$998K – – –
Two Sigma Investments
32
Two Sigma Investments
New York
$864K +$647K +244,630 +718%
Charles Schwab
33
Charles Schwab
California
$801K -$29.3K -11,070 -4%
XT
34
XTX Topco
Cayman Islands
$773K +$660K +249,412 New
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$770K +$581K +219,707 +763%
M&T Bank
36
M&T Bank
New York
$612K +$523K +197,682 New
BCM
37
Bridgeway Capital Management
Texas
$604K +$264K +99,900 +105%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$585K +$396K +149,800 +386%
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$574K +$40.8K +15,424 +9%
AQR Capital Management
40
AQR Capital Management
Connecticut
$489K +$378K +143,034 +979%
N
41
Nuveen
North Carolina
$474K +$1.72K +648 +0.4%
SSA
42
Schonfeld Strategic Advisors
New York
$440K +$187K +70,493 +99%
UBS Group
43
UBS Group
Switzerland
$396K -$41.8K -15,813 -11%
UOC
44
UBS O'Connor
Illinois
$391K +$333K +126,000 New
Bank of New York Mellon
45
Bank of New York Mellon
New York
$389K +$2.64K +997 +0.8%
Ameriprise
46
Ameriprise
Minnesota
$389K +$114K +43,195 +53%
NYLIM
47
New York Life Investment Management
New York
$225K -$4.87K -1,842 -2%
Assenagon Asset Management
48
Assenagon Asset Management
Luxembourg
$220K -$497K -187,724 -73%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$185K -$4.36K -1,646 -3%
AllianceBernstein
50
AllianceBernstein
Tennessee
$157K -$7.86K -2,970 -6%
1
2
3 4 5

PMVP Hedge Fund Activity: Q4 2023 in Review

98 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2023, worth a combined $145M — down 56% from $333M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of PMVP and 25 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 32 added.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $6.47M. The largest seller was Boxer Capital, exiting entirely with an estimated $19.4M sold.

  • 98 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2023, down from 104 in Q3 2023.
  • Funds reported $145M of PMV Pharmaceuticals stock for Q4 2023, down 56% quarter-over-quarter.
  • 25 funds opened new PMV Pharmaceuticals positions in Q4 2023 and 29 closed out, a net change of -4 holders.
  • The largest PMV Pharmaceuticals buyer in Q4 2023 was ArrowMark Colorado Holdings, an estimated $6.47M added.
  • The largest PMV Pharmaceuticals seller in Q4 2023 was Boxer Capital, an estimated $19.4M sold.

Based on aggregated 13F filings for Q4 2023.